Sulpiride and Trifluoperazine: interaction and safety

Interaction mechanism

Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Systemic QT-prolonging effects may add; low potassium and a slow heart rate increase concern. Additive central nervous system effects may worsen alertness and balance.

Clinical significance and safety

Sulpiride and Trifluoperazine: Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Systemic QT-prolonging effects may add; low potassium and a slow heart rate increase concern. Additive central nervous system effects may worsen alertness and balance. Drowsiness, dizziness, reduced coordination and falls can be more likely. Driving and other hazardous tasks require particular caution when affected. The class warning does not mean that every combination is contraindicated or that each pair has been tested in a separate clinical trial. The cited product information recommends avoiding the relevant QT-risk combination; it does not make every antipsychotic pair an absolute contraindication. Heart disease, a slow pulse and low potassium or magnesium can increase concern. A clinician determines whether ECG or electrolyte checks are needed. Fainting or new irregular palpitations require urgent assessment. Concurrent antipsychotic treatment or a planned switch requires specialist review of movement symptoms, alertness, balance and cardiac risk. A class precaution is not evidence that all such combinations are absolutely contraindicated.

Using this information

This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.